![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 22
2022
Schneider, A.; Fasshauer, E.; Scheiderbauer, J.; Warnke, C.; Koepke, S.; Kasper, J.; Toussaint, M.; Temmes, H.; Hemmer, B.; Schiffmann, I; Rahn, A. C. und Heesen, C.
(2022):
Development and evaluation of evidence-based patient information handbooks about multiple sclerosis immunotherapies.
In: Multiple Sclerosis and Related Disorders, Bd. 60, 103728
2021
Grahl, S.; Bussas, M.; Pongratz, V.; Kirschke, J. S.; Zimmer, C.; Berthele, A.; Hemmer, B. und Muehlau, M.
(2021):
T1-Weighted Intensity Increase After a Single Administration of a Linear Gadolinium-Based Contrast Agent in Multiple Sclerosis.
In: Clinical Neuroradiology, Bd. 31, Nr. 1: S. 235-243
[PDF, 2MB]
Kowarik, M. C.; Astling, D.; Lepennetier, G.; Ritchie, A.; Hemmer, B.; Owens, G. P. und Bennett, Jeffrey L.
(2021):
Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients.
In: Neurotherapeutics, Bd. 18, Nr. 1: S. 364-377
Grahl, S.; Bussas, M.; Wiestler, B.; Eichinger, P.; Gaser, C.; Kirschke, J.; Zimmer, C.; Berthele, A.; Hemmer, B. und Muehlau, M.
(2021):
Differential Effects of Fingolimod and Natalizumab on Magnetic Resonance Imaging Measures in Relapsing-Remitting Multiple Sclerosis.
In: Neurotherapeutics, Bd. 18, Nr. 4: S. 2589-2597
[PDF, 549kB]
2020
Richard, Yolande; Kemmerer, C. L.; Pernpeintner, V.; Ruschil, C.; Abdelhak, A.; Scholl, M.; Ziemann, U.; Krumbholz, M.; Hemmer, B. und Kowarik, M. C. 
ORCID: https://orcid.org/0000-0003-1389-5539
(2020):
Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
In: PLOS ONE 15(7), e0235449 [PDF, 1MB]
ORCID: https://orcid.org/0000-0003-1389-5539
(2020):
Differential effects of disease modifying drugs on peripheral blood B cell subsets: A cross sectional study in multiple sclerosis patients treated with interferon-β, glatiramer acetate, dimethyl fumarate, fingolimod or natalizumab.
In: PLOS ONE 15(7), e0235449 [PDF, 1MB]
Whittam, D. H. ORCID: https://orcid.org/0000-0002-9430-8190; Karthikeayan, V.; Gibbons, E.; Kneen, R.; Chandratre, S.; Ciccarelli, O.; Hacohen, Y.; de Seze, J.; Deiva, K.; Hintzen, R. Q.; Wildemann, B.; Jarius, S.; Kleiter, I.; Rostasy, K.; Huppke, P.; Hemmer, B.; Paul, F.; Aktas, O.; Pröbstel, A. K.; Arrambide, G.; Tintore, M.; Amato, M. P.; Nosadini, M.; Mancardi, M. M.; Capobianco, M.; Illes, Z.; Siva, A.; Altintas, A.; Akman-Demir, G.; Pandit, L.; Apiwattankul, M.; Hor, J. Y.; Viswanathan, S.; Qiu, W.; Kim, H. J.; Nakashima, I.; Fujihara, K.; Ramanathan, S.; Dale, R. C.; Boggild, M.; Broadley, S.; Lana-Peixoto, M. A.; Sato, D. K.; Tenembaum, S.; Cabre, P.; Wingerchuk, D. M.; Weinshenker, B. G.; Greenberg, B.; Matiello, M.; Klawiter, E. C.; Bennett, J. L.; Wallach, A. I.; Kister, I.; Banwell, B. L.; Traboulsee, A.; Pohl, D.; Palace, J.; Leite, M. I.; Levy, M.; Marignier, R.; Solomon, T.; Lim, M.; Huda, S. und Jacob, A.
(2020):
Treatment of MOG antibody associated disorders: results of an international survey.
In: Journal of Neurology, Bd. 267, Nr. 12: S. 3565-3577
ORCID: https://orcid.org/0000-0002-9430-8190; Karthikeayan, V.; Gibbons, E.; Kneen, R.; Chandratre, S.; Ciccarelli, O.; Hacohen, Y.; de Seze, J.; Deiva, K.; Hintzen, R. Q.; Wildemann, B.; Jarius, S.; Kleiter, I.; Rostasy, K.; Huppke, P.; Hemmer, B.; Paul, F.; Aktas, O.; Pröbstel, A. K.; Arrambide, G.; Tintore, M.; Amato, M. P.; Nosadini, M.; Mancardi, M. M.; Capobianco, M.; Illes, Z.; Siva, A.; Altintas, A.; Akman-Demir, G.; Pandit, L.; Apiwattankul, M.; Hor, J. Y.; Viswanathan, S.; Qiu, W.; Kim, H. J.; Nakashima, I.; Fujihara, K.; Ramanathan, S.; Dale, R. C.; Boggild, M.; Broadley, S.; Lana-Peixoto, M. A.; Sato, D. K.; Tenembaum, S.; Cabre, P.; Wingerchuk, D. M.; Weinshenker, B. G.; Greenberg, B.; Matiello, M.; Klawiter, E. C.; Bennett, J. L.; Wallach, A. I.; Kister, I.; Banwell, B. L.; Traboulsee, A.; Pohl, D.; Palace, J.; Leite, M. I.; Levy, M.; Marignier, R.; Solomon, T.; Lim, M.; Huda, S. und Jacob, A.
(2020):
Treatment of MOG antibody associated disorders: results of an international survey.
In: Journal of Neurology, Bd. 267, Nr. 12: S. 3565-3577
Aly, L.; Havla, J.; Lepennetier, G.; Andlauer, T. F. M.; Sie, C.; Strauss, E.-M.; Hoshi, M.-M.; Kuempfel, T.; Hiltensperger, M.; Mitsdoerffer, M.; Muehlau, M.; Zimmer, C.; Hemmer, B.; Korn, T. und Knier, B.
(2020):
Inner retinal layer thinning in radiologically isolated syndrome predicts conversion to multiple sclerosis.
In: European Journal of Neurology, Bd. 27, Nr. 11: S. 2217-2224
[PDF, 305kB]
2019
Grahl, S.; Pongratz, V; Schmidt, P.; Engl, C.; Bussas, M.; Radetz, A.; Gonzalez-Escamilla, G.; Groppa, S.; Zipp, F.; Lukas, C.; Kirschke, J.; Zimmer, C.; Hoshi, M.; Berthele, A.; Hemmer, B. und Muehlau, M.
(2019):
Evidence for a white matter lesion size threshold to support the diagnosis of relapsing remitting multiple sclerosis.
In: Multiple Sclerosis and Related Disorders, Bd. 29: S. 124-129
2018
Montalban, X.; Gold, R.; Thompson, A. J.; Otero-Romero, S.; Amato, M. P.; Chandraratna, D.; Clanet, M.; Comi, G.; Derfuss, T.; Fazekas, F.; Hartung, H. P.; Havrdova, E.; Hemmer, B.; Kappos, L.; Liblau, R.; Lubetzki, C.; Marcus, E.; Miller, D. H.; Olsson, T.; Pilling, S.; Selmaj, K.; Siva, A.; Sorensen, P. S.; Sormani, M. P.; Thalheim, C.; Wiendl, H. und Zipp, F.
(2018):
ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.
In: European Journal of Neurology, Bd. 25, Nr. 2: S. 215-237
2017
Biberacher, V.; Schmidt, P.; Grahl, S.; Beer, A.; Buck, D.; Berthele, A.; Hoshi, M.-M.; Kirschke, J.; Zimmer, C.; Hemmer, B. und Mühlau, M.
(2017):
Shrinking of T2-hyperintense white matter lesions in early multiple sclerosis.
In: Multiple Sclerosis Journal, Bd. 23: S. 261-262
Engl, C.; Bok, L.; Grahl, S.; Schmidt, P.; Biberacher, V.; Hoshi, M.-M.; Beer, A.; Kirschke, J. S.; Zimmer, C.; Hemmer, B. und Mühlau, M.
(2017):
Cognitive impairment in MS: are white matter lesions the main driver?
In: Multiple Sclerosis Journal, Bd. 23: S. 573-574
Grahl, S.; Biberacher, V.; Schmidt, P.; Engl, C.; Beer, A.; Kirschke, J. S.; Zimmer, C.; Hemmer, B. und Mühlau, M.
(2017):
Defining a minimal meaningful lesion size in multiple sclerosis.
In: Multiple Sclerosis Journal, Bd. 2017, Nr. 23, 238:
P538-237
Gasperi, C.; Salmen, A.; Antony, G.; Bayas, A.; Dankowski, T.; Heesen, C.; Kmpfel, T.; Linker, R. A.; Paul, F.; Stangel, M.; Tackenberg, B.; Bergh, F. Then; Tumani, H.; Warnke, C.; Weber, F.; Wiendl, H.; Wildemann, B.; Zettl, U. K.; Ziemann, U.; Zipp, F.; Gold, R. und Hemmer, B.
(2017):
Intrathecal immunoglobulin synthesis as a predictive marker for disability progression in multiple sclerosis.
In: Multiple Sclerosis Journal, Bd. 23: S. 301-303
Bismarck, O. von; Dankowski, T.; Antony, G.; Ambrosius, B.; Ziegler, A.; Zipp, F.; Tackenberg, B.; Bergh, F. Then; Tumani, H.; Kümpfel, T.; Stangel, M.; Heesen, C.; Wildemann, B.; Paul, F.; Bayas, A.; Warnke, C.; Weber, F.; Linker, R. A.; Ziemann, U.; Zettl, U. K.; Wiendl, H.; Hemmer, B.; Gold, R. und Salmen, A.
(2017):
Neuropsychological impairment in newly diagnosed early multiple sclerosis: clinical and neuropsychological characterization of a German cohort of 1124 patients.
In: Multiple Sclerosis Journal, Bd. 23: S. 165-166
Knier, B.; Hiltensperger, M.; Sie, C.; Aly, L.; Garg, G.; Ködel, U.; Gunzer, M.; Hemmer, B. und Korn, T.
(2017):
Unexpected role of neutrophil granulocytes during both murine and human central nervous system autoimmunity.
In: Multiple Sclerosis Journal, Bd. 23: S. 42
Grätz, C.; Gröger, A.; Salmen, A.; Zöller, D.; Schultz, J.; Siller, N.; Lüssi, F.; Fleischer, V.; Bellenberg, B.; Berthele, A.; Biberacher, V.; Havla, J.; Hecker, M.; Hohlfeld, R.; Infante-Duarte, C.; Kirschke, J. S.; Kümpfel, T.; Linker, R.; Paul, F.; Pfeuffer, S.; Sämann, P.; Weber, F.; Zettl, U. K.; Jahn-Eimermacher, A.; Antony, G.; Sergiu, G.; Wiendl, H.; Hemmer, B.; Mühlau, M.; Lukas, C.; Gold, R.; Lill, C. M. und Zipp, F.
(2017):
Association of smoking but not HLA-DRB1*15:01, APOE, or body mass index with brain atrophy in early multiple sclerosis.
In: Multiple Sclerosis Journal, Bd. 23: S. 184-185
Righart, R.; Schmidt, P.; Dahnke, R.; Biberacher, V.; Beer, A.; Buck, D.; Hemmer, B.; Kirschke, J. S.; Zimmer, C.; Gaser, C. und Mühlau, M.
(2017):
Volume versus surface-based cortical thickness measurements: A comparative study with healthy controls and multiple sclerosis patients.
In: PLOS One 12(7), e0179590 [PDF, 4MB]
In: PLOS One 12(7), e0179590 [PDF, 4MB]
2016
Biberacher, V.; Schmidt, P.; Selter, R. C.; Pernpeintner, V.; Kowarik, M. C.; Buck, D.; Korn, T.; Berthele, A.; Kirschke, J.; Zimmer, C.; Hemmer, B. und Mühlau, M.
(2016):
Chasing the driver of fatigue in multiple sclerosis: brain MRI versus CSF.
In: Multiple Sclerosis Journal, Bd. 22: S. 31-32
[PDF, 71kB]
Beer, A.; Biberacher, V.; Schmidt, P.; Righart, R.; Buck, D.; Berthele, A.; Kirschke, J.; Zimmer, C.; Hemmer, B. und Mühlau, M.
(2016):
Tissue damage within normal appearing white matter in early multiple sclerosis: assessment by the ratio of T1-and T2-weighted MR image intensity.
In: Journal of Neurology, Bd. 263, Nr. 8: S. 1495-1502
Gasperi, C.; Krysta, A.; Antony, G.; Bayas, A.; Gold, R.; Heesen, C.; Kümpfel, Tania; Linker, R. A.; Paul, F.; Stangel, M.; Tackenberg, B.; Bergh, F. Then; Tumani, H.; Warnke, C.; Weber, F.; Wick, W.; Wiendl, H.; Zettl, U. K.; Ziemann, U.; Zipp, F.; Buck, D. und Hemmer, B.
(2016):
Genetic variants associated with intrathecal synthesis of IgG, IgM and IgA in multiple sclerosis.
In: Multiple Sclerosis Journal, Bd. 22: S. 486-487
[PDF, 80kB]
Klotz, L.; Berthele, A.; Brück, W.; Chan, A.; Flachenecker, P.; Gold, R.; Haghikia, A.; Hellwig, K.; Hemmer, B.; Hohlfeld, R.; Korn, T.; Kümpfel, T.; Lang, M.; Limmroth, V.; Linker, R. A.; Meier, U.; Meuth, S. G.; Paul, F.; Salmen, A.; Stangel, M.; Tackenberg, B.; Tumani, H.; Warnke, C.; Weber, M. S.; Ziemssen, T.; Zipp, F. und Wiendl, H.
(2016):
Monitoring von Blutparametern unter verlaufsmodifizierender MS-Therapie. Substanzspezifische Relevanz und aktuelle Handlungsempfehlungen.
In: Nervenarzt, Bd. 87, Nr. 6: S. 645-659
2013
Havla, Joachim; Berthele, A.; Kümpfel, Tania; Krumbholz, Markus; Jochim, A.; Kronsbein, H.; Ryschkewitsch, C.; Jensen, P.; Lippmann, K.; Hemmer, B.; Major, E. und Hohlfeld, Reinhard
(August 2013):
Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab ``infusion group''.
In: Multiple Sclerosis Journal, Bd. 19, Nr. 9: S. 1213-1215
[PDF, 638kB]